{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-061110","form_type":"8-K","ticker":"RGNX","cik":"0001590877","company_name":"REGENXBIO Inc.","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.674777+00:00","generated_at":"2026-06-08T09:32:00.961356+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"REGENXBIO cuts 15% workforce, focuses on three lead gene therapies; Q3 net loss $61.9M","bullets":["Workforce reduction of ~15%, expected $100M cost savings over two years; cash runway extended into H2 2025.","Q3 revenue $28.9M (Zolgensma royalties $28.4M), net loss $61.9M ($1.41/share) vs $75.5M loss year ago.","Lead programs: ABBV-RGX-314 (wet AMD/DR), RGX-202 (Duchenne), RGX-121 (MPS II); strategic alternatives for others.","ABBV-RGX-314 suprachoroidal data: 89% risk reduction in vision-threatening events at one year for dose level 2.","Cash $364.5M as of Sep 30, 2023, down from $565.2M at Dec 31, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-061110","json":"https://secwatch.observer/filing/0000950170-23-061110.json","markdown":"https://secwatch.observer/filing/0000950170-23-061110.md","text":"https://secwatch.observer/filing/0000950170-23-061110.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590877/000095017023061110/0000950170-23-061110-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590877/000095017023061110/rgnx-20231108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T09:32:00.961356+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2e33049a3e15e4c10cbfa95fea4146d23ed6e2d2","claim":"REGENXBIO Inc. reported financial results for third quarter ended September 30, 2023.","evidence_excerpt":"REGENXBIO Inc. (the “Company”) issued a press release regarding its results of operations and financial condition for the quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1590877/000095017023061110/0000950170-23-061110-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}